Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Genentech unit forms alliance with Constellation Pharmaceuticals

Roche’s Genentech unit forms alliance with Constellation Pharmaceuticals

18th January 2012

Roche subsidiary Genentech has entered into a new drug discovery alliance with Constellation Pharmaceuticals, which will target cancer and other serious diseases.

The broad collaboration will utilise research into epigenetics and chromatin biology to identify innovative treatments over a three-year period, with Genentech also gaining an option to acquire Constellation if the research proceeds successfully.

A funding commitment of $95 million (61.84 million pounds) has been agreed, with Constellation also set to be eligible for substantial development and commercialisation milestone payments, as well as royalties on sales.

Should Genentech exercise its option to purchase the company, it would gain control of all of its current programmes, including its advanced BET chromatin reader and EZH2 chromatin writer protein projects.

Dr James Sabry, vice-president of Genentech Partnering, said: "We believe Constellation is a leading company in chromatin biology and epigenetics drug discovery and an excellent partner for Genentech in this area."

This follows the announcement of another collaboration agreement between Genentech and Vernalis earlier this month.ADNFCR-8000103-ID-801267668-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.